Related Experiment Video
Updated: Jun 1, 2026

Tracking Fibrinolysis of Chandler Loop-Formed Whole Blood Clots Under Shear Flow in An In-Vitro Thrombolysis Model
Published on: April 19, 2024
Thrombin-activatable fibrinolysis inhibitor in breast cancer patients
O Kaftan1, B Kasapoglu, M Koroglu
1Department of Internal Medicine, Fatih University Medical School, Ankara, Turkey.
Objective:
To evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) activity and also its relationship with other homeostasis markers in breast cancer patients.
Subjects And Methods:
Forty-two female patients with breast cancer and 24 healthy women (controls) were enrolled in the study and fasting blood samples of all cases were drawn from a large antecubital vein for assay of TAFI and other homeostasis tests.
Results:
The TAFI levels were 79.5 ± 15.5 and 39.3 ± 12.1 in patients and controls, respectively, and the difference was statistically significant (p < 0.001). In the patient group, the serum fibrinogen level was 504.9 ± 224.8, while in the control group it was 393.9 ± 100.5, and the difference was also statistically significant (p < 0.001).
Conclusion:
The data showed that increased levels of TAFI are a contributing factor of thrombotic disorders in breast cancer patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

